Get started
Author

Lars‐Olof Mügge

Observed names: L O Mügge, L-O Mügge, L.-O. Mügge, L.O. Mügge, Lars-Olof Mugge, Lars-Olof Mügge, Lars-Olof Mügge, Mügge, Lars-Olof
Observed institutions: University of Freiburg, Universität Ulm, University Medical Center Freiburg, Universitätsklinikum Würzburg, Jena University Hospital, Universitätsmedizin Rostock, Friedrich Schiller University Jena, Leipzig University
OpenAlex ID: A5111731084
Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia
2007 · Sebastian Scholl, Claudia Theuer, et al. · European Journal Of Haematology · 69
The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey
2019 · Annamaria Brioli, Maximilian Klaus, et al. · Annals of Hematology · 60
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
2022 · Meletios A Dimopoulos, Paul G Richardson, et al. · The Lancet Haematology · 50
PDF
Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).
2009 · Hermann Einsele, Peter Liebisch, et al. · Blood · 43
Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia
2007 · S. Scholl, L.-O. Mügge, et al. · Leukemia Research · 32
Safety and impact of donor‐type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch
2005 · Sebastian Scholl, Anne Klink, et al. · Transfusion · 30
Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors
2004 · C Kasper, H G Sayer, et al. · Bone Marrow Transplantation · 29
Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial
2020 · Sandra Maria Dold, Mandy-Deborah Möller, et al. · Haematologica · 25
PDF
Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT
2004 · S Scholl, L O Mügge, et al. · Bone Marrow Transplantation · 17
Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN)
2019 · Annamaria Brioli, Kirsi Manz, et al. · Journal of Cancer Research and Clinical Oncology · 15
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)
2017 · Juliane Beck, Andreas Schwarzer, et al. · Journal of Cancer Research and Clinical Oncology · 15
Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort
2022 · Annamaria Brioli, Theresa Maria Nägler, et al. · Oncology Research and Treatment · 14
Clonal T-LGL population mimicking leukemia in Felty’s syndrome—part of a continuous spectrum of T-LGL proliferations?
2013 · Karin G. Schrenk, Manuela Krokowski, et al. · Annals of Hematology · 14
Safety issues and management of toxicities associated with new treatments for multiple myeloma
2017 · Annamaria Brioli, Lars-Olof Mügge, et al. · Expert Review of Hematology · 10
Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients
2016 · Nils Winkelmann, Max Desole, et al. · Journal of Cancer Research and Clinical Oncology · 9
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
2023 · Dietger Niederwieser, Thomas Lang, et al. · Annals of Hematology · 8
PDF
Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients
2020 · Annamaria Brioli, Felix vom Hofe, et al. · Bone Marrow Transplantation · 8
A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010–2012
2015 · Georg Maschmeyer, Lars-Olof Mügge, et al. · Journal of Cancer Research and Clinical Oncology · 7
Sustained expression of nucleophosmin (NPM1) mutation at late relapse presenting as isolated myeloid sarcoma in a patient with acute myeloid leukemia
2007 · Sebastian Scholl, Joachim Lüftner, et al. · Annals of Hematology · 6
Der Einfluss von Operationslagerungen und Spinalanästhesie auf die Lungenfunktion
2001 · B Raßler, L-O Mügge, et al. · Pneumologie · 6
PDF
Response to Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Newly Diagnosed Multiple Myeloma Is Independent of Cytogenetic Risk and Retained after Double Stem Cell Transplant
2014 · Stefan Knop, Christian Langer, et al. · Blood · 5
Full Dose or Reduced Dose Melphalan (MEL) for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): A Single Center Analysis on 187 Consecutive Patients
2018 · Annamaria Brioli, vom Hofe Felix, et al. · Blood · 4
A case with coincidental diagnosis of primary central nervous system lymphoma and lymph node sarcoidosis
2010 · Eva J. Greiner, Lars-Olof Mügge, et al. · Journal of Neuro-Oncology · 4
Impact of Response in Patients (Pts) With Stem Cell Transplant (SCT)-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Treated With Continuous Lenalidomide + Low-Dose Dexamethasone (Rd) in the FIRST Trial
2015 · N. Bahlis, A. Corso, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Lower gastrointestinal bleeding in a patient with Crohn’s disease and plasma cell leukemia in remission
2015 · Karin G. Schrenk, Kathrin Katenkamp, et al. · Annals of Hematology · 2
Works count: 45
Citation count: 490
H-index: 13
I10-index: 14
Year
Topic
Type